<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1096">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146882</url>
  </required_header>
  <id_info>
    <org_study_id>DCR-A1AT-202</org_study_id>
    <secondary_id>STARLIGHT</secondary_id>
    <nct_id>NCT05146882</nct_id>
  </id_info>
  <brief_title>An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)</brief_title>
  <official_title>A Phase 2 Open-Label Extension Study to Evaluate the Safety and Pharmacodynamics of Belcesiran in Patients With PiZZ Alpha-1 Antitrypsin Deficiency Associated Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dicerna Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dicerna Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, open-label extension of Study DCR-A1AT-201, designed to&#xD;
      evaluate the long-term safety and further characterize the pharmacodynamics (PD) of&#xD;
      belcesiran in adult patients with PiZZ AATLD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">December 7, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of treatment-emergent adverse events</measure>
    <time_frame>up to 152 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in pulmonary function tests (PFTs)</measure>
    <time_frame>up to 152 weeks</time_frame>
    <description>Forced expiratory volume in 1 second (FEV1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in PFTs</measure>
    <time_frame>up to 152 weeks</time_frame>
    <description>Forced vital capacity (FVC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in PFTs</measure>
    <time_frame>up to 152 weeks</time_frame>
    <description>FEV1/FVC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in PFTs</measure>
    <time_frame>up to 152 weeks</time_frame>
    <description>diffusing capacity for carbon monoxide (DLCO)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in 12-lead electrocardiogram (ECG)</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in ECG</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>ventricular rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in 12-lead ECG</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>RR interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in 12-lead ECG</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>PR interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in 12-lead ECG</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>QRS duration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in 12-lead ECG</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>QT interval</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in 12-lead ECG</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>corrected QT interval (QTcF, Fridericia correction)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in physical examination (PE) findings</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>body weight</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in PE findings</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>body-mass index (BMI) (using height from DCR-A1AT-201 study)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in PE findings</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>physical examination to assess skin, lungs, cardiovascular system, and abdomen (liver and spleen) based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE; version 5.0) grading scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in vital sign measurements</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in vital sign measurements</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>pulse rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in vital sign measurements</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>respiratory rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in vital sign measurements</measure>
    <time_frame>up to 56 weeks</time_frame>
    <description>oral temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in clinical laboratory tests: Hematology</measure>
    <time_frame>up to 152 weeks</time_frame>
    <description>Hematology is collected to evaluate the long-term safety of belcesiran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in clinical laboratory tests: Clinical Chemistry</measure>
    <time_frame>up to 152 weeks</time_frame>
    <description>Clinical Chemistry is collected to evaluate the long-term safety of belcesiran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in clinical laboratory tests: Coagulation</measure>
    <time_frame>up to 152 weeks</time_frame>
    <description>Coagulation is collected to evaluate the long-term safety of belcesiran</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in clinical laboratory tests: Urinalysis</measure>
    <time_frame>up to 152 weeks</time_frame>
    <description>Urinalysis is collected to evaluate the long-term safety of belcesiran</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in serum AAT protein concentrations over time</measure>
    <time_frame>up to 152 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Alpha 1-Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>belcesiran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who completed the DCR-A1AT-201 treatment period will receive 210mg of open-label belcesiran administered subcutaneously every four weeks (q4w)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants who completed the DCR-A1AT-201 Conditional Follow-up period will enter DCR-A1AT-202 for continued follow-up (will not receive open-label belcesiran)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belcesiran</intervention_name>
    <description>Belcesiran will be administered subcutaneously (SC) in the treatment arm. Dose: 210 mg q4w.</description>
    <arm_group_label>belcesiran</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be 18 to 75 years of age inclusive, at the time of signing the Informed Consent&#xD;
             Form (ICF).&#xD;
&#xD;
          2. Documented diagnosis of PiZZ-type Alpha-1 Antitrypsin deficiency (AATD), confirmed by&#xD;
             genotyping.&#xD;
&#xD;
          3. Lung, renal and liver function within acceptable limits.&#xD;
&#xD;
          4. Capable of giving signed informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the ICF and in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any condition that, in the opinion of the Investigator, would make the participant&#xD;
             unsuitable for enrollment or could interfere with participation in or completion of&#xD;
             the study&#xD;
&#xD;
          2. Routine use of acetaminophen/paracetamol&#xD;
&#xD;
          3. Use of systemically acting steroids in the month prior to Screening and throughout the&#xD;
             study period.&#xD;
&#xD;
          4. Positive SARS-CoV-2 virus test at Screening&#xD;
&#xD;
          5. Any other safety laboratory test result considered clinically significant and&#xD;
             unacceptable by the Investigator&#xD;
&#xD;
          6. Inability or unwillingness to comply with the specified study procedures, including&#xD;
             lifestyle considerations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hardean Achneck, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dicerna Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

